Domestic pharma sale grows more than 13% in June after degrowth of last two months

After reporting a degrowth for two consecutive months, the domestic pharma retail market monthly sales resumed on growth trajectory reporting 13.2 per cent growth in June as compared to the same month last year. The pharma market went down 6.3 per cent in May this year followed by 9 per cent decline in April. Corresponding to the healthy monthly growth reported, the domestic pharmaceutical moving annual turnover (MAT) also witnessed an 8.3 per cent growth as compared to 8.1 per cent in May. Both acute and chronic therapies edged up 1.5 per cent and 0.4 per cent respectively leading to 1.1 per cent rise in overall sales in June as against May, according to the latest figures by market research firm IQVIA.

As per market annual turnover for June 2022, the Indian pharma market was valued at Rs. 185,023 crore. Except June 2020 and June 2022 witnessing 10.2 per cent and 1.1 per cent increase in overall sales respectively, June sales have always been lower than preceding May sales. However, June 2021 saw the steepest decline in sales.

The overall sale in June 2021 reported a 16.3 per cent decrease as compared to May 2021, stated IQVIA. June has consistently reported growth over the previous June month over the last five years. Acute and chronic drug segments reported a 13.2 per cent and 13.3 per cent rise respectively in June this year as compared to 15.7 per cent and 9.9 per cent increase in acute and chronic therapies respectively in the same month last year. Chronic segment has grown slightly faster at the rate of 9 per cent as compared to the acute segment, which has grown by 7.9 per cent in June this year.Anti-infective, gastrointestinal, vitamins/minerals/nutrients are the top 3 therapies of acute segment in June. However, gastrointestinal was ahead of anti-infective in May this year.

Cardiac, antidiabetic, neuro/CNS are the top 3 therapies in the chronic segment in June. Pain/analgesic grew the fastest at 24.4 per cent and urology grew at 16.5 per cent. However, cardiac contributed the maximum to chronic segment growth at 21.7 per cent followed by neuro/CNS at 19.3 per cent and anti-diabetic at16.2 per cent. In the acute segment in June, growth of Indian and MNC is very close. Indian companies have grown by 8.3 per cent while MNC have grown by 5.9 per cent. In the chronic segment, a big gap emerged in performance of Indian companies and MNC from 2020 and the gap is widening.

Indian companies have grown by 10.4 per cent while MNC have grown by 2.7 per cent in June 2022. On the moving annual turnover basis, La Renon, J B Pharma, Corona Remedies, Micro Labs and IPCA Labs were the top 5 fastest growing among the top 40 companies in the domestic pharma retail market in June. Aristo Pharma, Micro Labs and Corona Remedies gained 1 rank each to reach 11th, 19th and 36th position, respectively. Zydus Cadila, Sanofi and Systopic slipped 1 rank each to reach 12th, 20th and 37th position, respectively. Rest all companies maintained their respective ranks.

On a MAT basis, Ryzodeg, Udiliv, Pan, Ultracet and Zerodol-SP were the top 5 fastest growing brands in June among the top 40 brands in the domestic pharma market. Total 452 new products were launched in June this year. New brands launched in the last 12 month have clocked a sale of Rs. 1,052.4 crore as compared to Rs. 1,139.5 crore reported last month. New products contributed 7.5 per cent to domestic pharma market growth in June.

By value, it contributed 0.6 per cent to the pharma market. 59.7 per cent of new products by value were launched in the acute segment while 40.3 per cent by value were launched in the chronic segment in the last 12 months ending June. Rybelsus (Abbott), Toujeo (Sanofi), Dydrosure (Alkem), Divatrone (Jagsonpal) and Zuviston (Emcure) were the top June 2022 monthly sales among the brands launched in the last 12 months.